Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 13/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22874788 | 0.98 | OPRM1 (0.49) | OPRM1OPRL1OPRK1OPRD1SIGMAR1 | |
| SCHEMBL760258 | 0.95 | OPRM1 (0.46) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL14519152 | 0.94 | OPRM1 (0.47) | OPRM1OPRL1OPRK1OPRD1SIGMAR1 | |
| SCHEMBL824131 | 0.90 | OPRL1 (0.49) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL20756941 | 0.89 | OPRM1 (0.43) | OPRM1OPRL1OPRK1OPRD1CHRM2 | |
| SCHEMBL24267669 | 0.88 | OPRL1 (0.51) | OPRM1OPRL1OPRK1OPRD1SIGMAR1 | |
| SCHEMBL20756734 | 0.86 | OPRL1 (0.48) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL16980439 | 0.86 | DPP4 (0.41) | OPRM1OPRL1OPRK1OPRD1SIGMAR1 | |
| SCHEMBL24585209 | 0.86 | OPRM1 (0.54) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL27290705 | 0.85 | DPP4 (0.44) | OPRM1OPRL1OPRK1OPRD1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20150216168-A1 | USE OF SUBSTITUTED 2-AMIDOBENZIMIDAZOLES, 2-AMIDOBENZOXAZOLES AND 2-AMIDOBENZOTHIAZOLES OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218110-A1 | USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218110-A1 | USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150216168-A1 | USE OF SUBSTITUTED 2-AMIDOBENZIMIDAZOLES, 2-AMIDOBENZOXAZOLES AND 2-AMIDOBENZOTHIAZOLES OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-08-06 | — | — | US | disclosed |
| US-8202887-B2 | 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors | JANSSEN R&D IRELAND (IE) | 2012-06-19 | — | — | US | disclosed |
| US-20090209583-A1 | 2-(SUBSTITUTED-AMINO)-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-08-20 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209583-A1 | 2-(SUBSTITUTED-AMINO)-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | SPINT2, PEPD, DNPEP | OPRM1 4398/4885OPRL1 4135/4885OPRK1 3769/4885 |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | OPRM1 4854/4885OPRL1 4629/4885OPRK1 4691/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | OPRM1 3619/4885OPRL1 4502/4885OPRK1 3829/4885 |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | OPRM1 4373/4885OPRL1 2927/4885OPRK1 2682/4885 |
| US-20150218110-A1 | USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | GABBR1, GABRA1, GABRA6 | OPRM1 750/4885OPRL1 795/4885OPRK1 200/4885 |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | CRBN, IKZF1, IKZF3 | OPRM1 4416/4885OPRL1 2677/4885OPRK1 2813/4885 |
| US-20150216168-A1 | USE OF SUBSTITUTED 2-AMIDOBENZIMIDAZOLES, 2-AMIDOBENZOXAZOLES AND 2-AMIDOBENZOTHIAZOLES OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | ABAT, AAK1, AGXT | OPRM1 3432/4885OPRL1 3493/4885OPRK1 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.